Frequently Asked Questions about Regeneron Pharmaceuticals, Inc. (REGN)

Name: Regeneron Pharmaceuticals, Inc. (REGN) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does Regeneron Pharmaceuticals, Inc. (REGN) do?

Accepted Answer

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularizati...

Question 2

Is Regeneron Pharmaceuticals, Inc. (REGN) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of REGN reveals an Altman Z-Score of 7.56 and a Piotroski F-Score of 5/9. These metrics, combined with its 5-year revenue trend ($14.34B most recent), help investors decide if REGN fits their risk profile.

Question 3

What is the current P/E ratio for REGN?

Accepted Answer

As of the latest trading session, Regeneron Pharmaceuticals, Inc. (REGN) has a trailing P/E ratio of 17.43.

Question 4

Who is the CEO of Regeneron Pharmaceuticals, Inc.?

Accepted Answer

The current Chief Executive Officer of Regeneron Pharmaceuticals, Inc. is Leonard S. Schleifer.

Question 5

What was REGN's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, Regeneron Pharmaceuticals, Inc. reported annual revenues of $14.34B (2025), $14.20B (2024), $13.12B (2023), $12.17B (2022), $16.07B (2021) respectively.

Question 6

Does REGN pay a dividend?

Accepted Answer

Regeneron Pharmaceuticals, Inc. currently pays a dividend to its shareholders, with a trailing dividend yield of 0.47%.

Question 7

How much debt and cash flow does REGN have?

Accepted Answer

In its latest reporting period, Regeneron Pharmaceuticals, Inc. generated $4.08B in Free Cash Flow against a total debt load of $2.71B.

Question 8

What is the Price-to-Book (P/B) ratio of Regeneron Pharmaceuticals, Inc.?

Accepted Answer

The Price-to-Book (P/B) ratio for Regeneron Pharmaceuticals, Inc. (REGN) is currently 2.51.

Question 9

What is the Price-to-Sales (P/S) ratio of REGN?

Accepted Answer

Based on trailing twelve-month data, Regeneron Pharmaceuticals, Inc. (REGN) trades at a Price-to-Sales (P/S) ratio of 5.53.

Question 10

What is Regeneron Pharmaceuticals, Inc.'s Return on Equity (ROE)?

Accepted Answer

Regeneron Pharmaceuticals, Inc. (REGN) has a Return on Equity (ROE) of 14.83%, representing its profitability relative to shareholder equity.